Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Chemical modification or the reaction product thereof – e.g.,...
Reexamination Certificate
2007-03-13
2007-03-13
Mertz, Prema (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Chemical modification or the reaction product thereof, e.g.,...
C536S023400
Reexamination Certificate
active
10468370
ABSTRACT:
The invention relates to artificial modified proteins, preferably fusion proteins, having a reduced immunogenicity compared to the parent non-modified molecule when exposed to a species in vivo. The invention relates, above all, to novel immunoglobulin fusion proteins which essentially consist of an immunoglobulin molecule or a fragment thereof covalently fused via its C-terminus to the N-terminus of a biologically active non-immunoglobulin molecule, preferably a polypeptide or protein or a biologically active fragment thereof. In a specific embodiment, the invention relates to fusion proteins consisting of an Fc portion of an antibody which is fused as mentioned to the non-immunological target molecule which elicits biological or pharmacological efficacy. The molecules of the invention have amino acid sequences which are altered in one or more amino acid residue positions but have in principal the same biological activity as compared with the non-altered molecules. The changes are made in regions of the molecules which are identified as T-cell epitopes, which contribute to an immune reaction in a living host. Thus, the invention also relates to a novel method of making such fusion proteins by identifying said epitopes comprising calculation of T-cell epitope values for MHC Class II molecule binding sites in a peptide by computer-aided methods.
REFERENCES:
patent: WO 00/40615 (2000-07-01), None
Baker Matthew
Carr Francis J.
Carter Graham
Gillies Stephen
Hamilton Anita
Merck Patent GmbH
Mertz Prema
Olson & Hierl Ltd.
LandOfFree
Anti-KSA/IL-2 fusion proteins with reduced immunogenicity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-KSA/IL-2 fusion proteins with reduced immunogenicity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-KSA/IL-2 fusion proteins with reduced immunogenicity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3786178